A Real-World Effectiveness of Subcutaneous Immunotherapy on the Cost of Medication, Allergic Rhinitis, and Asthma Exacerbations, as well as Upper Respiratory Tract Infection in Subjects with Allergic Rhinitis with or without Asthma: A Retrospective Pilot Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Data Collection
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Wallace, D.V.; Dykewicz, M.S.; Bernstein, D.I.; Blessing-Moore, J.; Cox, L.; Khan, D.A.; Lang, D.M.; Nicklas, R.A.; Oppenheimer, J.; Portnoy, J.M.; et al. The diagnosis and management of rhinitis: An updated practice parameter. J. Allergy Clin. Immunol. 2008, 122 (Suppl. 2), S1–S84. [Google Scholar] [CrossRef]
- Pothirat, C.; Phetsuk, N.; Liwsrisakun, C.; Bumroongkit, C.; Deesomchok, A.; Theerakittikul, T. Major Chronic Respiratory Diseases in Chiang Mai: Prevalence, Clinical Characteristics, and Their Correlations. J. Med. Assoc. Thai. 2016, 99, 1005–1013. [Google Scholar]
- Pothirat, C.; Chaiwong, W. Aeroallergen sensitization and clinical characteristics of subjects with chronic rhinitis in Chiang Mai, Thailand: A Twenty-Year Retrospective Study. J. Asthma Allergy 2021, 14, 789–795. [Google Scholar] [CrossRef]
- Moote, W.; Kim, H. Allergen-specific immunotherapy. Allergy Asthma Clin. Immunol. 2011, 7 (Suppl. 1), S5. [Google Scholar] [CrossRef] [Green Version]
- Akdis, M.; Akdis, C.A. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J. Allergy Clin. Immunol. 2014, 133, 621–631. [Google Scholar] [CrossRef]
- Jutel, M.; Kosowska, A.; Smolinska, S. Allergen Immunotherapy: Past, Present, and Future. Allergy Asthma Immunol. Res. 2016, 8, 191–197. [Google Scholar] [CrossRef] [Green Version]
- Pajno, G.B.; Barberio, G.; De Luca, F.; Morabito, L.; Parmiani, S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 2001, 31, 1392–1397. [Google Scholar] [CrossRef]
- Purello-D’Ambrosio, F.; Gangemi, S.; Merendino, R.A.; Isola, S.; Puccinelli, P.; Parmiani, S.; Ricciardi, L. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy 2001, 31, 1295–1302. [Google Scholar] [CrossRef]
- Droessaert, V.; Timmermans, M.; Dekimpe, E.; Seys, S.; Ceuppens, J.J.; Fokkens, W.J.; Hellings, P.W. Real-life study showing better control of allergic rhinitis by immunotherapy than regular pharmacotherapy. Rhinology 2016, 54, 214–220. [Google Scholar] [CrossRef]
- Lu, Y.; Xu, L.; Xia, M.; Li, Y.; Cao, L. The efficacy and safety of subcutaneous immunotherapy in mite-sensitized subjects with asthma: A meta-analysis. Respir. Care 2015, 60, 269–278. [Google Scholar] [CrossRef]
- Targowski, T.; Jahnz-Rózyk, K.; Przekora, P.; Kucharczyk, A.; Owczarek, W. Clinical efficacy and costs of the three-year specific allergen immunotherapy—Retrospective study. Pol. Merkur. Lekarski. 2011, 31, 106–110. [Google Scholar]
- Tu, Y.; Zhang, H.; Zhao, L.; Jin, P.; Zi, X.; Li, T.; Shi, L.; Zhi, L. The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: A two-year, observational study. J. Laryngol. Otol. 2019, 133, 213–219. [Google Scholar] [CrossRef]
- Dominguez-Ortega, J.; Delgado, J.; Blanco, C.; Prieto, L.; Arroabarren, E.; Cimarra, M.; Henriquez-Santana, A.; Iglesias-Souto, J.; Vega-Chicote, J.M.; Tabar, A.I. Specific allergen immunotherapy for the treatment of allergic asthma: A review of current evidence. J. Investig. Allergol. Clin. Immunol. 2017, 27 (Suppl. 1), 1–35. [Google Scholar] [CrossRef] [Green Version]
- Abramson, M.J.; Puy, R.M.; Weiner, J.M. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 2000, 2, CD001186. [Google Scholar]
- Asaria, M.; Dhami, S.; van Ree, R.; van Wijk, G.R.; Muraro, A.; Roberts, G.; Sheikh, A. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy 2018, 73, 269–283. [Google Scholar] [CrossRef] [Green Version]
- Rottem, M.; Egbarya, A. Subcutaneous immunotherapy in Northern Israel: Efficacy and safety. Isr. Med. Assoc. J. 2014, 16, 539–543. [Google Scholar]
- Petersen, K.D.; Gyrd-Hansen, D.; Dahl, R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol. Immunopathol. 2005, 33, 296–302. [Google Scholar] [CrossRef]
- Thanborisutkul, K.; Khodtecha, N.; Kulalert, P.; Sritipsukho, P. Efficacy, patients’ perception, and cost of medication in allergic rhinitis with subcutaneous immunotherapy. Asian Pac. J. Allergy Immunol. 2020. [Google Scholar] [CrossRef]
- Rantala, A.; Jaakkola, J.J.; Jaakkola, M.S. Respiratory infections in adults with atopic disease and IgE antibodies to common aeroallergens. PLoS ONE 2013, 8, e68582. [Google Scholar] [CrossRef] [Green Version]
- Reinhold, T.; Ostermann, J.; Thum-Oltmer, S.; Brüggenjürgen, B. Influence of subcutaneous specific immunotherapy on drug costs in children suffering from allergic asthma. Clin. Transl. Allergy 2013, 3, 30. [Google Scholar] [CrossRef] [Green Version]
- Pifferi, M.; Baldini, G.; Marrazzini, G.; Baldini, M.; Ragazzo, V.; Pietrobelli, A.; Boner, A.L. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: A three-year prospective study. Allergy 2002, 57, 785–790. [Google Scholar] [CrossRef]
- Gilmour, M.I. Influence of air pollutants on allergic sensitization: The paradox of increased allergies and decreased resistance to infection. Toxicol. Pathol. 2012, 40, 312–314. [Google Scholar] [CrossRef]
- Dhami, S.; Kakourou, A.; Asamoah, F.; Agache, I.; Lau, S.; Jutel, M.; Muraro, A.; Roberts, G.; Akdis, C.A.; Bonini, M.; et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy 2017, 72, 1825–1848. [Google Scholar] [CrossRef]
- Fajt, M.L.; Rosenberg, S.L.; Yecies, E.; Traister, R.S.; Petrov, A.A. A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol. Allergy Asthma Proc. 2017, 38, 309–316. [Google Scholar] [CrossRef]
Phase | Injection Number | Concentration | Volume (mL) | Interval |
---|---|---|---|---|
Induction | 1 | 1:100,000 | 0.1 | 1 week |
2 | 1:100,000 | 0.2 | 1 week | |
3 | 1:100,000 | 0.3 | 1 week | |
4 | 1:100,000 | 0.4 | 1 week | |
5 | 1:100,000 | 0.5 | 1 week | |
6 | 1:10,000 | 0.1 | 1 week | |
7 | 1:10,000 | 0.2 | 1 week | |
8 | 1:10,000 | 0.3 | 1 week | |
9 | 1:10,000 | 0.4 | 1 week | |
10 | 1:10,000 | 0.5 | 1 week | |
11 | 1:1000 | 0.1 | 1 week | |
12 | 1:1000 | 0.2 | 1 week | |
13 | 1:1000 | 0.3 | 1 week | |
14 | 1:1000 | 0.4 | 1 week | |
15 | 1:1000 | 0.5 | 1 week | |
16 | 1:100 | 0.1 | 2 week | |
17 | 1:100 | 0.2 | 2 week | |
Maintenance | 18 | 1:100 | 0.3 | 4 week |
Up to 3 years | 1:100 | 0.3 | 4 week |
Characteristics | SCIT (N = 24) | SUC (N = 16) | p-Value |
---|---|---|---|
Age (year) | 34.3 ± 14.1 | 29.4 ± 18.1 | 0.333 |
Gender (male), n (%) | 9 (37.5) | 8 (50.0) | 0.522 |
Body mass index (kg/m2) | 22.4 ± 3.1 | 20.6 ± 3.6 | 0.109 |
Age of disease onset (year) (median, IQR) | 15.0 (9.3–29.5) | 17.0 (5.3–32.0) | 0.795 |
Duration of allergic rhinitis or asthma (year) (median, IQR) | 11.5 (9.0–18.3) | 7.5 (5.0–8.0) | <0.001 |
Family history of AR or asthma, n (%) | 18 (75.0) | 12 (75.0) | 1.000 |
Aeroallergen sensitization, n (%) | |||
Mite mixed | 22 (91.7) | 16 (100.0) | 0.508 |
Cockroaches mixed | 14 (58.3) | 13 (81.3) | 0.177 |
Animal dander | 2 (8.3) | 1 (6.2) | 0.810 |
Grass pollen | 4 (16.7) | 5 (31.3) | 0.441 |
AR with asthma, n (%) | 15 (62.5) | 10 (62.5) | 1.000 |
Spirometry results | |||
%predicted of FVC | 86.9 ± 9.6 | 89.6 ± 16.0 | 0.67 |
%predicted of FEV1 | 88.3 ± 13.7 | 82.4 ± 9.7 | 0.338 |
Ratio of FEV1 to FVC (%) | 85.6 ± 7.5 | 80.4 ± 7.7 | 0.393 |
Total Subjects | SCIT (N = 24) | SUC (N = 16) | p-Value |
---|---|---|---|
Baseline | 1822.5 (1504.9–2129.5) | 1562.4 (1315.1–1857.3) | 0.162 |
1st year | 587.4 (348.3–1374.6) ** | 1562.4 (1315.1–1857.3) | <0.001 |
2nd year | 501.2 (302.9–839.0) ** | 1728.3 (1190.0–2236.1) | <0.001 |
3rd year | 372.4 (284.8–752.4) ** | 1500.3 (1217.9–1748.9) | <0.001 |
AR with Asthma Subjects | SCIT (N = 15) | SUC (N = 10) | p-Value |
Baseline | 1938.5 (1725.7–2806.9) | 1649.6 (1447.5–2052.7) | 0.219 |
1st year | 644.6 (432.9–1532.5) * | 1649.6 (1447.5–2052.7) | 0.006 |
2nd year | 601.0 (284.7–1331.0) * | 1802.9 (1303.0–2415.1) | 0.001 |
3rd year | 563.9 (350.0–937.8) * | 1512.3 (1290.7–2072.8) | 0.005 |
Total Subjects | SCIT (N = 24) | SUC (N = 16) | p-Value |
---|---|---|---|
Baseline | 1.0 (0.0–3.0) | 0.0 (0.0–1.8) | 0.084 |
1st year | 0.0 (0.0–1.0) ** | 0.0 (0.0–1.8) | 0.449 |
2nd year | 0.0 (0.0–1.0) ** | 0.0 (0.0–1.0) | 0.413 |
3rd year | 0.0 (0.0–1.0) ** | 1.0 (0.0–1.0) | 0.101 |
AR with Asthma Subjects | SCIT (N = 15) | SUC (N = 10) | p-Value |
Baseline | 1.5 (0.0–3.0) | 0.5 (0.0–1.3) | 0.208 |
1st year | 0.0 (0.0–1.0) * | 0.5 (0.0–1.3) | 0.393 |
2nd year | 0.0 (0.0–1.0) * | 0.0 (0.0–1.3) | 0.58 |
3rd year | 0.0 (0.0–0.0) * | 1.0 (0.0–1.5) | 0.032 |
Total Subjects | SCIT (N = 24) | SUC (N = 16) | p-Value |
---|---|---|---|
Baseline | 1.0 (0.0–2.0) | 0.0 (0.0–2.0) | 0.291 |
1st year | 0.5 (0.0–1.8) | 0.0 (0.0–2.0) | 0.998 |
2nd year | 1.0 (0.0–1.0) * | 1.0 (0.0–2.8) | 0.367 |
3rd year | 0.0 (0.0–1.0) * | 1.0 (0.0–3.0) | 0.113 |
AR with Asthma Subjects | SCIT (N = 15) | SUC (N = 10) | p-Value |
Baseline | 2.0 (0.0–3.3) | 0.0 (0.0–2.0) | 0.074 |
1st year | 1.0 (0.0–2.0) | 0.0 (0.0–2.0) | 0.329 |
2nd year | 1.0 (0.0–1.0) | 0.0 (0.0–3.0) | 0.615 |
3rd year | 0.0 (0.0–1.0) * | 0.0 (0.0–1.5) | 0.712 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pothirat, C.; Chaiwong, W. A Real-World Effectiveness of Subcutaneous Immunotherapy on the Cost of Medication, Allergic Rhinitis, and Asthma Exacerbations, as well as Upper Respiratory Tract Infection in Subjects with Allergic Rhinitis with or without Asthma: A Retrospective Pilot Study. Medicina 2021, 57, 1229. https://doi.org/10.3390/medicina57111229
Pothirat C, Chaiwong W. A Real-World Effectiveness of Subcutaneous Immunotherapy on the Cost of Medication, Allergic Rhinitis, and Asthma Exacerbations, as well as Upper Respiratory Tract Infection in Subjects with Allergic Rhinitis with or without Asthma: A Retrospective Pilot Study. Medicina. 2021; 57(11):1229. https://doi.org/10.3390/medicina57111229
Chicago/Turabian StylePothirat, Chaicharn, and Warawut Chaiwong. 2021. "A Real-World Effectiveness of Subcutaneous Immunotherapy on the Cost of Medication, Allergic Rhinitis, and Asthma Exacerbations, as well as Upper Respiratory Tract Infection in Subjects with Allergic Rhinitis with or without Asthma: A Retrospective Pilot Study" Medicina 57, no. 11: 1229. https://doi.org/10.3390/medicina57111229